Markku Jalkanen, the chief executive officer of Faron Pharmaceuticals Oy (AIM:FARN, OTC:FPHAF) talks to Proactive’s Katie Pilbeam about the significance of the company being given the green light by regulators in the US and Finland to begin an early-stage clinical trial of its immuno-oncology drug candidate.
Faron Pharmaceuticals Oy excited by green light for trials of promising anti-cancer treatment
